Todd Skaar

Professor of Medicine

Indiana University School of Medicine
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe. Healthy participants received a single oral dose of tolbutamide (250 mg) with a single 600 mg dose of efavirenz (SD) before and after 600 mg daily efavirenz for 17 days (MD). Tolbutamide, efavirenz, and their metabolites were quantified in plasma and urine samples by LC–MS/MS method. Participants were genotyped for CYP2C9*2 and *3 and for CYP2B6*4, *9, and *18. Pharmacokinetic data were valid for 71 and 59 participants for SD‐ and MD groups, respectively. MD efavirenz caused more than 50% increase in median tolbutamide AUC 0‐∞ and C 24 in all subjects, and 1.42–1.46‐fold increase in the paired analysis ( p < 0.0001); tolbutamide/metabolite ratios were also increased ( p < 0.001), while tolbutamide's CL/F/kg, metabolite formation clearance, and metabolite C max were significantly reduced. CYP2C9 genetic variants were associated with reduced tolbutamide elimination compared to *1/*1 and *1/*2 (slowest, *3/*3; and intermediate, *1/*3, *2/*2, and *2/*3). The lowest percent change occurred in *2/*2 and * 3/*3 genotypes, though small sample sizes limited reliable assessment of genotype‐specific DDI effects. In conclusion, chronic efavirenz use inhibits CYP2C9 activity in vivo. This inhibition may increase the risk of adverse effects from narrow‐therapeutic‐index CYP2C9 substrates (e.g., warfarin, phenytoin, and sulfonylureas). Therefore, therapeutic drug monitoring and dose adjustments are warranted when efavirenz is co‐administered with these medications.

Year:

2026

PURPOSE Docetaxel-related toxicities can limit cancer treatment and be fatal. It is metabolized by the cytochrome P450 3A4 enzyme. We evaluated the association of rare reduced-function CYP3A4 variants with grade 3-4 docetaxel-induced toxicity. METHODS We analyzed data from the SUCCESS-A breast cancer study available from the Database for Genotypes and Phenotypes. In our retrospective, case-control analysis of the data, 3,208 patients were enrolled in the original study, received docetaxel, and had genetic data and associated docetaxel-induced toxicity outcomes available. CYP3A4 genotypes were not originally determined for individuals in the SUCCESS-A study, so we imputed CYP3A4 genotypes using the TOPMed imputation server. The development of grade 3-4 docetaxel-induced hematological toxicities in patients with two copies of the reduced-function CYP3A4*22 allele were compared with those with normal function alleles. RESULTS Eight individuals had imputed CYP3A4*22 / *22 genotypes. Six of them (75%) experienced grade 3-4 toxicities. In comparison, 56% of the CYP3A4*1 / *1 (normal function alleles) participants (n = 1,628; P = .31, odds ratio [OR], 2.41 [95% CI, 0.43 to 24.49) and 50.9% (n = 145) of the CYP3A4*1 / *22 participants developed grade 3-4 toxicities ( P = .11, OR, 1.23 [95% CI, 0.96 to 1.58]). CONCLUSION Although not statistically significant, patients with the rare CYP3A4*22 / *22 genotypes may be at increased risks of severe toxicities.

Year:

2026

Types of medical services for cancer treatment, including ambulatory gastrointestinal surgeries, cancer pharmacotherapy administration, cancer radiation therapy, and non-operative diagnostic testing and laboratory

Year:

2025

Types of medical services including facility, auxiliary, and professional services in 3 clinical care settings, whose charges and out-of-pocket payments are elements of the medical service costs

Year:

2025

Estimated association of metastasis and other factors with the pre–post proportional increases in outpatient prescription charges and OOP expenses. Estimated relative ratio of proportional increase in pre– and post–colorectal cancer (CRC) prescription charges and OOP expenses associated with each factor, with 95% CIs, two-sided P value, and illustrative plots. Ref, reference. *, P P P

Year:

2025

Treatment component, care setting, treatment modality, and metastasis status. A, Percent of patients receiving a treatment component and encountering a care setting. B, Correlations among metastasis diagnosis, treatment, and care-setting encounters. C, First-year treatment modalities for non-mCRC and mCRC patients. Note: small numbers of patients were suppressed in compliance with Optum CDM’s DUA. Chemo-pharma, pharmacotherapy; DUA, data use agreement; NA, not available.

Year:

2025

Colorectal cancer is a leading cause of cancer-related death and among the costliest cancers to treat in the United States. As advanced-stage diagnoses increase, the initial-care cost differences between metastatic (mCRC) and nonmetastatic colorectal cancer (non-mCRC) remain unclear, limiting insights into the financial impact of metastasis and late detection. Using Optum’s de-identified Clinformatics Data Mart, the largest US commercial claims database, we examined first-year costs of care for patients aged ≥45 years newly diagnosed with colorectal cancer between 2017 and 2023, with at least 1 year of medical records before and after diagnosis. Multivariate linear mixed-effects models estimated the impact of metastasis on medical and prescription charges and out-of-pocket expenses (2023 USD) in relation to treatment components, emergency department (ED) visits, hospitalizations, and hospice care. Among 25,169 patients, 32.8% had metastasis at diagnosis. Treatment and care utilization were consistently higher for patients with mCRC, with the greatest disparity in pharmacotherapy use (79.1% vs. 26.9%), followed by ED visits (65.4% vs. 48.1%), hospitalizations (91.1% vs. 84%), radiotherapy, and hospice care. Medical and prescription charges for patients with mCRC ($353,255 and $5,745) were nearly double than those for non-mCRC ($182,000 and $2,406), as were out-of-pocket expenses ($4,032 vs. $2,144 for medical; $319 vs. $188 for prescriptions). Pharmacotherapy was the primary cost driver in mCRC, followed by hospitalizations and ED visits. Initial-care medical and prescription costs were substantially higher for patients with mCRC. These findings underscore the economic burden of metastasis, highlighting potential benefits and cost savings of early detection and intervention strategies such as routine screening. Significance: This study highlights the substantial economic burden of mCRC, with medical and prescription costs nearly twice those of nonmetastatic cases. The findings underscore the financial and clinical benefits of early detection and timely intervention, reinforcing the importance of routine colorectal cancer screening to reduce late-stage disease incidence.

Year:

2025

Derivation of new colorectal cancer (CRC) cases with and without metastasis. Flow diagram presenting steps to extract newly diagnosed colorectal cancer cases and to classify into nonmetastasis and metastasis incidences. AFHSD, The Armed Forces Health Surveillance Division (a partner with the Centers for Disease Control and Prevention on health surveillance and matters).

Year:

2025

Estimated association of metastasis and other factors with the pre–post proportional increases in medical service charges and OOP expenses. Estimated relative ratio of proportional increase in pre– and post–colorectal cancer (CRC) medical charges and OOP expenses associated with each factor, with 95% CIs, two-sided P value, and illustrative plots. Ref, reference. *, P P P

Year:

2025

A list of ICD-10-CM diagnosis codes for primary invasive colorectal cancer following case identification and Incident rules of colorectal cancer by AFHSD, and ICD-10-CM diagnosis codes for metastasis cancers by HCUP

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (16)

George Sledge

-

UNITED STATES
View details

Fei Shen

Indiana University Bloomington

UNITED STATES
View details

Paul Gerardo Yeh

Instructional Assistant Professor

University of Texas System

UNITED STATES
View details

Jeffrey Berenberg

Professor

University of Hawai'i Cancer Center

UNITED STATES
View details

Zeruesenay Desta

Professor of Medicine

Indiana University

UNITED STATES
View details

Travis S Johnson

Assistant Research Professor

Indiana University School of Medicine

UNITED STATES
View details

Lynne I. Wagner

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Joseph A. Sparano

Chief, Division of Hematology/Oncology; Deputy Director, Tisch Cancer Institute

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Charles Loprinzi

Regis Professor of Breast Cancer Oncology

Mayo Clinic

UNITED STATES
View details

Erica Cantor

Indiana University Bloomington

UNITED STATES
View details

Vered Stearns

Weill Cornell Medicine

UNITED STATES
View details

Hongmei Nan

Professor

University of Indianapolis

UNITED STATES
View details

Al B. Benson

Professor/Attending

Northwestern University

UNITED STATES
View details

Kathy Miller

Indiana University Bloomington

UNITED STATES
View details

Chi M. Nguyen

Assistant Research Professor

Indiana University School of Medicine

UNITED STATES
View details

N Lynn Henry

University of Michigan

UNITED STATES
View details